Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview

Adaptimmune Therapeutics

08/08/2025 22:22

Adaptimmune Therapeutics PLC ADAP.OQ ADAP.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Abingdon Oxfordshire-based  company is expected to report a 92.3% decrease in revenue to $9.914 million from $128.23 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Adaptimmune Therapeutics PLC is for a loss of 10 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Adaptimmune Therapeutics PLC is $0.48, about 82.7% above its last closing price of $0.08

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.12
-0.15
-0.19
Missed
-27.4
Dec. 31 2025
-0.13
-0.24
Missed
-78.6
Sep. 30 2024
-0.12
-0.13
-0.01
Beat
92.2​
Jun. 30 2024
-0.05
-0.07
0.24
Beat
434.9
​​Mar. 31 2024
-0.07
-0.10
-0.18
Missed
-83.7
Dec. 31 2023
-0.08
-0.10
-0.24
Missed
-140​
Sep. 30 2023
-0.12
-0.14
-0.20
Missed
-45.5
Jun. 30 2023
-0.12
-0.13
-0.23
Missed
-72.8

This summary was machine generated August 8 at 21:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)